4-(5-甲酰基-1-咪唑甲基)苯甲腈 | 183500-37-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(5-甲酰基-1-咪唑甲基)苯甲腈
• 英文名称: 4-[(5-formyl-1H-imidazol-1-yl)methyl]benzonitrile
• 英文别名: 1-(4-cyano)benzyl-5-formylimidazole；4-(5-Formyl-imidazol-1-ylmethyl)-benzonitrile；4-[(5-formylimidazol-1-yl)methyl]benzonitrile
• CAS: 183500-37-0
• 化学式: C₁₂H₉N₃O
• mdl: MFCD06657146
• 分子量: 211.223
• InChiKey: AMUOEEKBBOOOCV-UHFFFAOYSA-N

物化性质

• 熔点：
  135-136 °C
• 沸点：
  467.6±30.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5-甲酰基-1-咪唑甲基)苯甲腈 在 sodium hydroxide 、 3 A molecular sieve 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 28.0h， 生成 2-(benzoyl-{1-[3-(4-cyano-benzyl)-3H-imidazol-4-ylmethyl]-piperidin-4-yl}-amino)-4-methylsulfanyl-butyric acid
  参考文献：
  名称：

  Potent and Selective Farnesyl Transferase Inhibitors

  摘要：

  We recently described a novel series of CA(1)A(2)X peptidomimetics as farnesyl transferase inhibitors (FTIs). These compounds possess an N-(4-piperidinyl)benzamide scaffold mimicking A(1)A(2) residue. Extensive exploration of structure-activity relationships revealed that replacement of cysteine by substituted benzylimidazoles provided nanomolar FTIs with in vitro activities (18e, IC50 = 4.60 nM on isolated enzyme, EC50 = 20.0 nM for growth inhibition on a tumor cell line). The molecular docking of 18e and 19e in the active site of the enzyme provided details of key interactions with the protein and showed that the methionine or phenylalanine residue fits into the aryl binding site.

  DOI：

  10.1021/jm030502y
• 作为产物：
  描述：

  4-(5-acetoxymethylimidazol-1-ylmethyl)benzonitrile hydrobromide 在 lithium hydroxide monohydrate 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 二甲基亚砜 为溶剂， 生成 4-(5-甲酰基-1-咪唑甲基)苯甲腈
  参考文献：
  名称：

  Inhibitors of farnesyl-protein transferase

  摘要：

  本发明涉及抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras法尼酰化的化合物。该发明还涉及含有本发明化合物的化疗组合物以及抑制法尼基-蛋白转移酶和致癌基因蛋白Ras法尼酰化的方法。

  公开号：

  US05891889A1

文献信息

• Inhibitors of farnesyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US06001835A1

  公开（公告）日：1999-12-14

  The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

  本发明涉及抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼醇化的化合物。该发明进一步涉及含有本发明化合物的化疗组合物以及用于抑制法尼基-蛋白转移酶和致癌基因蛋白Ras的法尼醇化的方法。
• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins
  申请人：——

  公开号：US20040204417A1

  公开（公告）日：2004-10-14

  The invention concerns compounds of general formula (1), wherein, in particular; W represents H, SO 2 R 5 . CO(CH 2 ) n R 5 , (CH 2 ) n R 6 , CS(CH 2 ) n R 5 ; X represents S or NH; Y represents (CH 2 ) p , CO, (CH 2 ) p CO, CH═CH—CO; Z represents a hetcrocycle, imidazole, benzimidazole, isoxazole, tetrazole, oxadiazole, thiadazole, pyridine, quinazoline, quinoxaline, quinoline, thiophene; R 1 represents COOR 6 , CONR 6 R 7 , CO—NH—CH(R 6 )—COOR 7 , CH 2 NR 6 R 7 , CH 2 OR 6 , (CH 2 ) p R 6 , CH═CHR 6 ; R 2 represents in particular hydrogen, C 1 -C 10 alkyl, a substituted or unsubstituted phenyl; R 5 and R 6 represents hydrogen, C 1 —C 6 alkyl; R 5 represents a substituted or unsubstituted phenyl or naphthyl; R 6 and R 7 , identical or different, represent hydrogen, C 1 —C 15 alkyl, a hetcrocycle. an aryl; n represents 0 to 10; p represents 1 to 6. 1

  该发明涉及一般式（1）的化合物，其中，特别是；W代表H，SO2R5.CO(CH2)nR5，(CH2)nR6，CS(CH2)nR5；X代表S或NH；Y代表(CH2)p，CO，(CH2)pCO，CH═CH—CO；Z代表杂环，咪唑，苯并咪唑，异噁唑，四唑，噁二唑，硫唑，吡啶，喹唑啉，喹喔啉，喹啉，噻吩；R1代表COOR6，CONR6R7，CO—NH—CH(R6)—COOR7，CH2NR6R7，CH2OR6，(CH2)pR6，CH═CHR6；R2特指氢，C1-C10烷基，取代或未取代苯基；R5和R6代表氢，C1—C6烷基；R5代表取代或未取代苯基或萘基；R6和R7，相同或不同，代表氢，C1—C15烷基，杂环，芳基；n表示0到10；p表示1到6。
• Farnesyltransferase inhibitors
  申请人：——

  公开号：US20030216441A1

  公开（公告）日：2003-11-20

  Compounds having the formula 1 are farnesyltransferase inhibitors. Also disclosed are methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物是法尼西基转移酶抑制剂。还公开了制备这些化合物的方法、含有这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。
• Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors
  作者：Qun Li、Keith W. Woods、Weibo Wang、Nan-Horng Lin、Akiyo Claiborne、Wen-zhen Gu、Jerry Cohen、Vincent S. Stoll、Charles Hutchins、David Frost、Saul H. Rosenberg、Hing L. Sham

  DOI：10.1016/j.bmcl.2005.02.062

  日期：2005.4

  Beginning with the structure of tipifarnib (1), a series of inhibitors of FTase have been synthesized by transposition of the D-ring to the imidazole and subsequent modification of the 2-quinolone motif. The compounds in the new series may be achiral and have structural features that allow for analogs that are difficult or impossible to make in the tertiary carbon-based tipifarnib series. The most

  从替非法尼（1）的结构开始，已通过将D环转位至咪唑并随后修饰了2-喹诺酮基序，合成了一系列FTase抑制剂。新系列中的化合物可能是非手性的，其结构特征使得难以或不可能在基于叔碳的替非法尼系列中制备类似物。最有效的化合物（4d）在体外对FTase的活性是Tipifarnib的4倍。